Therapeutic Potential of Refanalin in Pulmonary Fibrosis

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43HL076959-01A1
Agency Tracking Number: HL076959
Amount: $175,272.00
Phase: Phase I
Program: SBIR
Awards Year: 2004
Solicitation Year: 2004
Solicitation Topic Code: N/A
Solicitation Number: PHS2004-2
Small Business Information
ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP, 350 COMMUNITY DR, RM 129, MANHASSET, NY, 11030
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 LATHA Paka
 (516) 562-1278
 SPAKA@ANGION.COM
Business Contact
 ITZHAK GOLDBERG
Phone: (516) 869-6400
Email: GOLDBERG@ANGION.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a devastating disease with less than a 50% five-year survival. While steroids and other immunosuppressive agents serve as the standard treatment for IPF, these agents have pro

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government